Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,654
archived clinical trials in
Cardiology

Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Status: Enrolling
Updated:  12/31/1969
Delray Medical Center
948
mi
from 43215
Delray Beach, FL
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Status: Enrolling
Updated: 12/31/1969
Delray Medical Center
948
mi
from 43215
Delray Beach, FL
Click here to add this to my saved trials
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Status: Enrolling
Updated:  12/31/1969
Iowa Heart Center, P.C.
573
mi
from 43215
West Des Moines, IA
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Status: Enrolling
Updated: 12/31/1969
Iowa Heart Center, P.C.
573
mi
from 43215
West Des Moines, IA
Click here to add this to my saved trials
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Status: Enrolling
Updated:  12/31/1969
Henry Ford Hospital
166
mi
from 43215
Detroit, MI
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Status: Enrolling
Updated: 12/31/1969
Henry Ford Hospital
166
mi
from 43215
Detroit, MI
Click here to add this to my saved trials
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Status: Enrolling
Updated:  12/31/1969
Univ of Nebraska Med Ctr
682
mi
from 43215
Omaha, NE
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Status: Enrolling
Updated: 12/31/1969
Univ of Nebraska Med Ctr
682
mi
from 43215
Omaha, NE
Click here to add this to my saved trials
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Status: Enrolling
Updated:  12/31/1969
Lourdes Cardiology Services
425
mi
from 43215
Voorhees, NJ
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Status: Enrolling
Updated: 12/31/1969
Lourdes Cardiology Services
425
mi
from 43215
Voorhees, NJ
Click here to add this to my saved trials
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Status: Enrolling
Updated:  12/31/1969
New Mexico Heart Institute
1333
mi
from 43215
Albuquerque, NM
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Status: Enrolling
Updated: 12/31/1969
New Mexico Heart Institute
1333
mi
from 43215
Albuquerque, NM
Click here to add this to my saved trials
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Status: Enrolling
Updated:  12/31/1969
North Shore University Hospital
493
mi
from 43215
Manhasset, NY
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Status: Enrolling
Updated: 12/31/1969
North Shore University Hospital
493
mi
from 43215
Manhasset, NY
Click here to add this to my saved trials
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Status: Enrolling
Updated:  12/31/1969
Wake Forest University Medical Center Clinical Sciences
mi
from 43215
Winston-Salem, NC
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Status: Enrolling
Updated: 12/31/1969
Wake Forest University Medical Center Clinical Sciences
mi
from 43215
Winston-Salem, NC
Click here to add this to my saved trials
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Status: Enrolling
Updated:  12/31/1969
University of Cincinnati
98
mi
from 43215
Cincinnati, OH
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Status: Enrolling
Updated: 12/31/1969
University of Cincinnati
98
mi
from 43215
Cincinnati, OH
Click here to add this to my saved trials
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Status: Enrolling
Updated:  12/31/1969
Lancaster General Hospital
353
mi
from 43215
Lancaster, PA
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Status: Enrolling
Updated: 12/31/1969
Lancaster General Hospital
353
mi
from 43215
Lancaster, PA
Click here to add this to my saved trials
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Status: Enrolling
Updated:  12/31/1969
Lankenau Medical Center
410
mi
from 43215
Wynnewood, PA
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Status: Enrolling
Updated: 12/31/1969
Lankenau Medical Center
410
mi
from 43215
Wynnewood, PA
Click here to add this to my saved trials
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Status: Enrolling
Updated:  12/31/1969
Centennial Medical Center
333
mi
from 43215
Nashville, TN
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Status: Enrolling
Updated: 12/31/1969
Centennial Medical Center
333
mi
from 43215
Nashville, TN
Click here to add this to my saved trials
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Status: Enrolling
Updated:  12/31/1969
Sentara Norfolk General Hospital
422
mi
from 43215
Norfolk, VA
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Status: Enrolling
Updated: 12/31/1969
Sentara Norfolk General Hospital
422
mi
from 43215
Norfolk, VA
Click here to add this to my saved trials
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Status: Enrolling
Updated:  12/31/1969
Cedars-Sinai Medical Center
1972
mi
from 43215
Los Angeles, CA
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Status: Enrolling
Updated: 12/31/1969
Cedars-Sinai Medical Center
1972
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Status: Enrolling
Updated:  12/31/1969
St.Joseph Hospital
1959
mi
from 43215
Orange, CA
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Status: Enrolling
Updated: 12/31/1969
St.Joseph Hospital
1959
mi
from 43215
Orange, CA
Click here to add this to my saved trials
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Status: Enrolling
Updated:  12/31/1969
Louisiana State University Health Sciences Center
798
mi
from 43215
New Orleans, LA
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Status: Enrolling
Updated: 12/31/1969
Louisiana State University Health Sciences Center
798
mi
from 43215
New Orleans, LA
Click here to add this to my saved trials
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Status: Enrolling
Updated:  12/31/1969
Ochsner Medical Center
799
mi
from 43215
New Orleans, LA
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Status: Enrolling
Updated: 12/31/1969
Ochsner Medical Center
799
mi
from 43215
New Orleans, LA
Click here to add this to my saved trials
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Status: Enrolling
Updated:  12/31/1969
Tufts Medical Center
642
mi
from 43215
Boston, MA
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Status: Enrolling
Updated: 12/31/1969
Tufts Medical Center
642
mi
from 43215
Boston, MA
Click here to add this to my saved trials
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Status: Enrolling
Updated:  12/31/1969
ST. Luke's Hospital
619
mi
from 43215
Kansas City, MO
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Status: Enrolling
Updated: 12/31/1969
ST. Luke's Hospital
619
mi
from 43215
Kansas City, MO
Click here to add this to my saved trials
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Status: Enrolling
Updated:  12/31/1969
Barnes Jewish Hospital
397
mi
from 43215
Saint Louis, MO
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Status: Enrolling
Updated: 12/31/1969
Barnes Jewish Hospital
397
mi
from 43215
Saint Louis, MO
Click here to add this to my saved trials
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Status: Enrolling
Updated:  12/31/1969
Atlantic Health System - Morristown Memorial Hospital
453
mi
from 43215
Morristown, NJ
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Status: Enrolling
Updated: 12/31/1969
Atlantic Health System - Morristown Memorial Hospital
453
mi
from 43215
Morristown, NJ
Click here to add this to my saved trials
Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients With Giant Cell Arteritis
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
955
mi
from 43215
Boca Raton, FL
Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients With Giant Cell Arteritis
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
955
mi
from 43215
Boca Raton, FL
Click here to add this to my saved trials
Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients With Giant Cell Arteritis
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
958
mi
from 43215
Naples, FL
Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients With Giant Cell Arteritis
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
958
mi
from 43215
Naples, FL
Click here to add this to my saved trials
Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients With Giant Cell Arteritis
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
460
mi
from 43215
Iowa City, IA
Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients With Giant Cell Arteritis
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
460
mi
from 43215
Iowa City, IA
Click here to add this to my saved trials
Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients With Giant Cell Arteritis
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
361
mi
from 43215
Paducah, KY
Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients With Giant Cell Arteritis
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
361
mi
from 43215
Paducah, KY
Click here to add this to my saved trials
Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients With Giant Cell Arteritis
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
624
mi
from 43215
Edina, MN
Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients With Giant Cell Arteritis
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
624
mi
from 43215
Edina, MN
Click here to add this to my saved trials
Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients With Giant Cell Arteritis
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
609
mi
from 43215
Lebanon, NH
Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients With Giant Cell Arteritis
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
609
mi
from 43215
Lebanon, NH
Click here to add this to my saved trials
Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients With Giant Cell Arteritis
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
481
mi
from 43215
New York, NY
Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients With Giant Cell Arteritis
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
481
mi
from 43215
New York, NY
Click here to add this to my saved trials
Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients With Giant Cell Arteritis
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
304
mi
from 43215
Asheville, NC
Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients With Giant Cell Arteritis
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
304
mi
from 43215
Asheville, NC
Click here to add this to my saved trials
Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients With Giant Cell Arteritis
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
488
mi
from 43215
Wilmington, NC
Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients With Giant Cell Arteritis
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
488
mi
from 43215
Wilmington, NC
Click here to add this to my saved trials
Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients With Giant Cell Arteritis
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
414
mi
from 43215
Philadelphia, PA
Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients With Giant Cell Arteritis
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
414
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients With Giant Cell Arteritis
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
436
mi
from 43215
Jackson, TN
Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients With Giant Cell Arteritis
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
436
mi
from 43215
Jackson, TN
Click here to add this to my saved trials
Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients With Giant Cell Arteritis
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2007
mi
from 43215
Seattle, WA
Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients With Giant Cell Arteritis
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2007
mi
from 43215
Seattle, WA
Click here to add this to my saved trials
Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients With Giant Cell Arteritis
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2018
mi
from 43215
Vancouver, WA
Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients With Giant Cell Arteritis
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2018
mi
from 43215
Vancouver, WA
Click here to add this to my saved trials
Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients With Giant Cell Arteritis
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1984
mi
from 43215
Santa Monica, CA
Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients With Giant Cell Arteritis
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1984
mi
from 43215
Santa Monica, CA
Click here to add this to my saved trials
Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients With Giant Cell Arteritis
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
643
mi
from 43215
Boston, MA
Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients With Giant Cell Arteritis
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients With Giant Cell Arteritis
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
559
mi
from 43215
Rochester, MN
Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients With Giant Cell Arteritis
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
559
mi
from 43215
Rochester, MN
Click here to add this to my saved trials
Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients With Giant Cell Arteritis
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1155
mi
from 43215
Aurora, CO
Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients With Giant Cell Arteritis
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1155
mi
from 43215
Aurora, CO
Click here to add this to my saved trials
Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients With Giant Cell Arteritis
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
704
mi
from 43215
Portland, ME
Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients With Giant Cell Arteritis
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
704
mi
from 43215
Portland, ME
Click here to add this to my saved trials
Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients With Giant Cell Arteritis
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
905
mi
from 43215
Dallas, TX
Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients With Giant Cell Arteritis
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
905
mi
from 43215
Dallas, TX
Click here to add this to my saved trials
Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients With Giant Cell Arteritis
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
9459
mi
from 43215
Camperdown,
Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients With Giant Cell Arteritis
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
9459
mi
from 43215
Camperdown,
Click here to add this to my saved trials
Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients With Giant Cell Arteritis
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
175
mi
from 43215
Saint Clair Shores, MI
Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients With Giant Cell Arteritis
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
175
mi
from 43215
Saint Clair Shores, MI
Click here to add this to my saved trials
In-Stent Restenosis Post-Approval Study
Post-Approval Study of the GORE® VIABAHN® Endoprosthesis for the Treatment of In-Stent Restenosis (ISR) in the Superficial Femoral Artery (SFA)
Status: Enrolling
Updated:  12/31/1969
Cardiovascular Institute of the South
838
mi
from 43215
Houma, LA
In-Stent Restenosis Post-Approval Study
Post-Approval Study of the GORE® VIABAHN® Endoprosthesis for the Treatment of In-Stent Restenosis (ISR) in the Superficial Femoral Artery (SFA)
Status: Enrolling
Updated: 12/31/1969
Cardiovascular Institute of the South
838
mi
from 43215
Houma, LA
Click here to add this to my saved trials
In-Stent Restenosis Post-Approval Study
Post-Approval Study of the GORE® VIABAHN® Endoprosthesis for the Treatment of In-Stent Restenosis (ISR) in the Superficial Femoral Artery (SFA)
Status: Enrolling
Updated:  12/31/1969
Greenville Hospital System
354
mi
from 43215
Greenville, SC
In-Stent Restenosis Post-Approval Study
Post-Approval Study of the GORE® VIABAHN® Endoprosthesis for the Treatment of In-Stent Restenosis (ISR) in the Superficial Femoral Artery (SFA)
Status: Enrolling
Updated: 12/31/1969
Greenville Hospital System
354
mi
from 43215
Greenville, SC
Click here to add this to my saved trials
In-Stent Restenosis Post-Approval Study
Post-Approval Study of the GORE® VIABAHN® Endoprosthesis for the Treatment of In-Stent Restenosis (ISR) in the Superficial Femoral Artery (SFA)
Status: Enrolling
Updated:  12/31/1969
Cardiology Associates of Mobile, Inc.
708
mi
from 43215
Fairhope, AL
In-Stent Restenosis Post-Approval Study
Post-Approval Study of the GORE® VIABAHN® Endoprosthesis for the Treatment of In-Stent Restenosis (ISR) in the Superficial Femoral Artery (SFA)
Status: Enrolling
Updated: 12/31/1969
Cardiology Associates of Mobile, Inc.
708
mi
from 43215
Fairhope, AL
Click here to add this to my saved trials
In-Stent Restenosis Post-Approval Study
Post-Approval Study of the GORE® VIABAHN® Endoprosthesis for the Treatment of In-Stent Restenosis (ISR) in the Superficial Femoral Artery (SFA)
Status: Enrolling
Updated:  12/31/1969
Rockford Cardiovascular Associates
352
mi
from 43215
Rockford, IL
In-Stent Restenosis Post-Approval Study
Post-Approval Study of the GORE® VIABAHN® Endoprosthesis for the Treatment of In-Stent Restenosis (ISR) in the Superficial Femoral Artery (SFA)
Status: Enrolling
Updated: 12/31/1969
Rockford Cardiovascular Associates
352
mi
from 43215
Rockford, IL
Click here to add this to my saved trials
In-Stent Restenosis Post-Approval Study
Post-Approval Study of the GORE® VIABAHN® Endoprosthesis for the Treatment of In-Stent Restenosis (ISR) in the Superficial Femoral Artery (SFA)
Status: Enrolling
Updated:  12/31/1969
Munson Medical Center
356
mi
from 43215
Traverse City, MI
In-Stent Restenosis Post-Approval Study
Post-Approval Study of the GORE® VIABAHN® Endoprosthesis for the Treatment of In-Stent Restenosis (ISR) in the Superficial Femoral Artery (SFA)
Status: Enrolling
Updated: 12/31/1969
Munson Medical Center
356
mi
from 43215
Traverse City, MI
Click here to add this to my saved trials
In-Stent Restenosis Post-Approval Study
Post-Approval Study of the GORE® VIABAHN® Endoprosthesis for the Treatment of In-Stent Restenosis (ISR) in the Superficial Femoral Artery (SFA)
Status: Enrolling
Updated:  12/31/1969
New York University Langone Medical Center
479
mi
from 43215
New York, NY
In-Stent Restenosis Post-Approval Study
Post-Approval Study of the GORE® VIABAHN® Endoprosthesis for the Treatment of In-Stent Restenosis (ISR) in the Superficial Femoral Artery (SFA)
Status: Enrolling
Updated: 12/31/1969
New York University Langone Medical Center
479
mi
from 43215
New York, NY
Click here to add this to my saved trials
In-Stent Restenosis Post-Approval Study
Post-Approval Study of the GORE® VIABAHN® Endoprosthesis for the Treatment of In-Stent Restenosis (ISR) in the Superficial Femoral Artery (SFA)
Status: Enrolling
Updated:  12/31/1969
St. Vincent's Consultants in Cardiovascular Disease
212
mi
from 43215
Erie, PA
In-Stent Restenosis Post-Approval Study
Post-Approval Study of the GORE® VIABAHN® Endoprosthesis for the Treatment of In-Stent Restenosis (ISR) in the Superficial Femoral Artery (SFA)
Status: Enrolling
Updated: 12/31/1969
St. Vincent's Consultants in Cardiovascular Disease
212
mi
from 43215
Erie, PA
Click here to add this to my saved trials
In-Stent Restenosis Post-Approval Study
Post-Approval Study of the GORE® VIABAHN® Endoprosthesis for the Treatment of In-Stent Restenosis (ISR) in the Superficial Femoral Artery (SFA)
Status: Enrolling
Updated:  12/31/1969
Miriam Hospital
619
mi
from 43215
Providence, RI
In-Stent Restenosis Post-Approval Study
Post-Approval Study of the GORE® VIABAHN® Endoprosthesis for the Treatment of In-Stent Restenosis (ISR) in the Superficial Femoral Artery (SFA)
Status: Enrolling
Updated: 12/31/1969
Miriam Hospital
619
mi
from 43215
Providence, RI
Click here to add this to my saved trials